ATE439836T1 - Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel - Google Patents

Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel

Info

Publication number
ATE439836T1
ATE439836T1 AT04767442T AT04767442T ATE439836T1 AT E439836 T1 ATE439836 T1 AT E439836T1 AT 04767442 T AT04767442 T AT 04767442T AT 04767442 T AT04767442 T AT 04767442T AT E439836 T1 ATE439836 T1 AT E439836T1
Authority
AT
Austria
Prior art keywords
composition containing
anticancer agent
phosphatase inhibitor
cdc25 phosphatase
cdc25
Prior art date
Application number
AT04767442T
Other languages
German (de)
English (en)
Inventor
Gregoire Prevost
Pannetier Marie-Christine Brezak
Christian Diolez
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE439836T1 publication Critical patent/ATE439836T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04767442T 2003-06-25 2004-06-24 Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel ATE439836T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
PCT/FR2004/001586 WO2005000852A2 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux

Publications (1)

Publication Number Publication Date
ATE439836T1 true ATE439836T1 (de) 2009-09-15

Family

ID=33515382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04767442T ATE439836T1 (de) 2003-06-25 2004-06-24 Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel

Country Status (14)

Country Link
US (3) US20060281736A1 (enExample)
EP (3) EP2335702A1 (enExample)
JP (2) JP2007514639A (enExample)
AR (2) AR044930A1 (enExample)
AT (1) ATE439836T1 (enExample)
CA (1) CA2530668A1 (enExample)
DE (1) DE602004022674D1 (enExample)
DK (1) DK1641453T3 (enExample)
ES (1) ES2332137T3 (enExample)
FR (1) FR2856688B1 (enExample)
MX (1) MXPA06000216A (enExample)
MY (1) MY141725A (enExample)
PL (1) PL1641453T3 (enExample)
WO (1) WO2005000852A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0215336A (pt) * 2001-12-27 2004-11-16 Scras Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
DE10353792A1 (de) 2003-11-13 2005-06-23 Exner, Heinrich, Dr.med.vet. Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion
FR2877667B1 (fr) * 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
FR2879598B1 (fr) * 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2190924B1 (de) * 2007-09-06 2011-05-25 Basf Se Blends aus verzweigten polyarylethern und hydrophilen polymeren
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
BR122017028566B1 (pt) * 2010-11-12 2022-03-03 Pharma Mar, S.A. Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um antibiótico anticâncer e kit
EP3615030A1 (en) 2017-04-24 2020-03-04 Novartis AG Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof
WO2021067572A2 (en) * 2019-10-01 2021-04-08 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo
EP4061372A1 (en) 2019-11-21 2022-09-28 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
US11981645B1 (en) 2023-10-10 2024-05-14 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735674A (en) * 1902-01-29 1903-08-04 William C Matthias Sparking igniter for explosive-engines.
FR50000E (fr) 1938-11-29 1939-09-29 Moulin à café
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6383871B1 (en) * 1999-08-31 2002-05-07 Micron Technology, Inc. Method of forming multiple oxide thicknesses for merged memory and logic applications
DE60016625T2 (de) * 1999-11-09 2005-12-22 Societe De Conseils De Recherches Et D'applications Scientifiques(S.C.R.A.S.) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs-mittel zu einer therapeutischen verwendung in der krebsbehandlung
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
WO2002050079A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
BR0215336A (pt) * 2001-12-27 2004-11-16 Scras Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
JP4273056B2 (ja) * 2004-08-12 2009-06-03 不二越機械工業株式会社 研磨装置

Also Published As

Publication number Publication date
FR2856688B1 (fr) 2008-05-30
WO2005000852A2 (fr) 2005-01-06
US20060281736A1 (en) 2006-12-14
FR2856688A1 (fr) 2004-12-31
PL1641453T3 (pl) 2010-01-29
JP2007514639A (ja) 2007-06-07
EP1641453B1 (fr) 2009-08-19
US20090253685A1 (en) 2009-10-08
MY141725A (en) 2010-06-15
ES2332137T3 (es) 2010-01-27
US20090137596A1 (en) 2009-05-28
JP2009149694A (ja) 2009-07-09
CA2530668A1 (fr) 2005-01-06
EP2335702A1 (fr) 2011-06-22
DE602004022674D1 (de) 2009-10-01
WO2005000852A3 (fr) 2005-06-30
AR044930A1 (es) 2005-10-12
AR070977A2 (es) 2010-05-19
MXPA06000216A (es) 2006-04-11
EP1641453A2 (fr) 2006-04-05
DK1641453T3 (da) 2009-12-14
EP1792905A1 (fr) 2007-06-06

Similar Documents

Publication Publication Date Title
ATE439836T1 (de) Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel
ATE466855T1 (de) Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
EP1781098A4 (en) ANTIMICROBIAL DEVICES AND COMPOSITIONS THEREFOR
ATE361053T1 (de) Kits für die mundpflege und zusammensetzungen
PL2277976T3 (pl) Kompozycje zawierające HFC-1234ZE i smar
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
DE60325255D1 (de) Duftzusammensetzung
DK1370633T3 (da) Smöremiddelsammensætning
IL217315A0 (en) Tetracycline derivatives and compositions comprising the same
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
DE60205746D1 (de) Planetengetriebe
ATE367143T1 (de) Schweisshemmende oder deodorierende zusammensetzungen
IL174863A0 (en) Compounds that inhibit serine proteases and pharmaceutical compositions containing the same
DE60333020D1 (de) Anzeigeeinrichtung des dünnen typs
EP1680535A4 (en) METHODS AND COMPOSITIONS FOR GALVANOPLASTY
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
ATE230255T1 (de) Zusammensetzung die ein trübungs- oder perlglanzmittel und mindestens einen fettalkohol enthällt
EP1512408A4 (en) ANTIBACTERIAL AGENT AND ANTIBACTERIAL COMPOSITION
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
EP1544279A4 (en) LUBRICANT COMPOSITION
ATE539138T1 (de) Schmierstoffzusammensetzungen
ATE352301T1 (de) Antineoplastische zusammensetzungen
IL174445A0 (en) Substituted isoquinolinone derivatives and pharmaceutical compositions containing the same
DE60232673D1 (de) Zusammensetzungen, die combretastatin und krebsbekämpfendes mittel enthalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties